AZ Clears Out Three Respiratory Drugs With Sale To Covis
The drug giant's strategy of divesting old assets continues apace with the $350m sale of the ciclesonide-based drugs Alvesco, Omnaris and Zetonna to the Swiss specialty pharma group.
You may also be interested in...
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Swedish Orphan Biovitrum gains a boost to its US commercialization infrastructure, a product to make immunology a key part of its specialty care business, and financial flexibility to seek further product acquisitions, through an RSV products deal with AstraZeneca.
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.